Patents Examined by Traviss C. McIntosh, III
  • Patent number: 11608353
    Abstract: There are provided compounds of Formula I: various compositions thereof and methods for their use in the inhibition of ?-amylase.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 21, 2023
    Inventors: Stephen G. Withers, Gary D. Brayer, Leslie Karen Williams, Xiaohua Zhang
  • Patent number: 11603416
    Abstract: The present disclosure discloses a method for preparation of derivatives of gram-positive bacteria surface capsular polysaccharide, and belongs to the field of carbohydrate chemistry. The present disclosure takes glucose as a glycosyl donor to obtain a target ?-glucosidic bond, then successfully synthesizes a disaccharide building block through a method of redox of a glucose C-2 site, and then takes the disaccharide building block as a repeat unit to synthesize a target oligosaccharide structure such as a derivative [?3)-?-D-Manp-(1?4)-?-D-Rhap-(1?]5-Linker of gram-positive bacteria cell wall capsular polysaccharide. A reduction end of decose is linked with a linker to be linked with a protein to make glycoconjugates for immunological studies. The method provided by the present disclosure is simple, time-saving, labor-saving and low-cost, and the resultant derivatives of the gram-positive bacteria surface capsular polysaccharide may be used for development and preparation of medicine related to autism.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: March 14, 2023
    Assignee: Jiangnan University
    Inventors: Jian Yin, Jing Hu, Juntao Cai
  • Patent number: 11597746
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I), wherein R1, R1?, X1, B1, R2, R2?, B2, X2, R3, Z-M-Y, and Y1-M1-Z1 are as defined herein.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: March 7, 2023
    Assignee: Janssen Biotech, Inc.
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James P. Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Gilles Bignan, Wim Bert Griet Schepens, Marcel Viellevoye, Johannes Wilhelmus J. F. Thuring
  • Patent number: 11597741
    Abstract: A process and materials method for making a glucose tetraester may include reacting glucose with a carboxylic acid to create a glucose pentaester. The glucose pentaester was reacted with a basic reagent to create a glucose tetraester. Glucose was reacted with a carboxylic acid anhydride in the presence of 4-dimethylaminopyridine to create a glucose pentaester product. The glucose pentaester reaction product was separated. The glucose pentaester reaction product was reacted with a basic reagent, wherein the reaction steps may take place at a temperature of about 0° C. to about 60° C. and about ambient pressure, wherein the ratio of the carboxylic acid to the glucose was from about 5:1 to about 50:1, and wherein the ratio of the glucose pentaester to the basic reagent was from about 1:50 to about 1:150.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 7, 2023
    Assignee: Myst Labs Inc.
    Inventor: Chenyue Xing
  • Patent number: 11597926
    Abstract: The present invention relates to a compound of formula (II) or (IIb) Wherein X, Y, Rx, Ry, R5 and Nu are as defined in the description and in the claims. The compound of formula (II) can be used in the manufacture of oligonucleotides.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 7, 2023
    Inventors: Konrad Bleicher, Joerg Duschmalé, Martina Brigitte Duschmalé, Henrik Frydenlund Hansen, Troels Koch, Meiling Li, Adrian Schaeublin, Xi Shu, Yong Wu
  • Patent number: 11576894
    Abstract: The present invention is directed to co-therapy and methods for the treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. The present invention is further directed to pharmaceutical compositions for the co-therapy and methods described herein.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: February 14, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yin Liang, John Ryan, Abraham B. Woldu, Lisa Wu
  • Patent number: 11566039
    Abstract: Provided are lincosamide compounds for the treatment of infectious diseases. The lincosamides described herein are modified at the C-7 position of the aminooctose (northern) region, thus distinguishing them from lincomycin and clindamycin. Also provided are methods for preparing the lincosamide compounds, pharmaceutical compositions comprising the lincosamide compounds, and methods of treating infectious diseases using the disclosed lincosamide compounds.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: January 31, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew G. Myers, Matthew James Mitcheltree
  • Patent number: 11555015
    Abstract: The present invention relates to certain compounds of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor: Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, an inflammatory skin disease or disorder, cancer, psoriasis, atopic dermatitis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, and acne, microbial infections or diseases and viral infections or diseases.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: January 17, 2023
    Assignee: Arena Pharmaceuticals, Inc.
    Inventors: Abu J. M. Sadeque, Daniel J. Buzard
  • Patent number: 11547698
    Abstract: The disclosure discloses an aryl hydrocarbon receptor modulators of formula (I), and pharmaceutically acceptable salts, R? is H, CN, CH2(OH)R0, CmH2m+1, CnH2n-1, CnH2n-3, two Ra is independently H, or two Ra together form ?O or ?N—W3—R1; A is a C6 to C10 aromatic ring, or a C2 to C10 heteroaromatic ring containing 1 to 5 heteroatom from N, O and S, or 4 to 7 membered non-aromatic heterocyclic ring containing 1 to 3 heteroatom from N, O and S and C?N, which are with no substituent or substituted by 1 or 3 R; Q is R, or a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring containing 1 to 5 heteroatom selected from N, O and S, which are with no substituent or substituted by 1 or 3 R; R is Rc connected with C or RN connected with N.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: January 10, 2023
    Assignee: ARIAGEN, INC.
    Inventors: Luqing Yang, Guodong Li, Suoming Zhang
  • Patent number: 11542292
    Abstract: Provided a polymerizable compound represented by the following Formula A-1 or Formula A-2: In Formula A-1 or Formula A-2, R1 represents an electron-donating group; n represents an integer from 1 to 5; R2 represents a hydrogen atom, a halogen atom, or —ORO, wherein RO represents a hydrogen atom, an alkyl group, or a protecting group of a hydroxy group; R3 represents a hydrogen atom or a protecting group of a hydroxy group; and X represents a structure represented by any one of Formula B-1 to Formula B-5.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: January 3, 2023
    Inventors: Takeshi Wada, Tatsuya Saito, Yuka Ishii, Yohei Nukaga
  • Patent number: 11535645
    Abstract: A compound has the following formula (I) or formula (II), an isomer thereof, a tautomer thereof, a pharmaceutical acceptable solvate thereof, or a pharmaceutical acceptable prodrug thereof.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: December 27, 2022
    Inventor: Xibin Liao
  • Patent number: 11535644
    Abstract: The invention relates to a crystalline methanol or dimethyl sulfoxide solvated form of regadenoson and an anhydrous polymorph of regadenoson. The invention is also directed to the preparation of the methanol or dimethyl sulfoxide solvated and anhydrous solid-state forms of regadenoson. In particular, the invention relates to the preparation of the anhydrous polymorph of regadenoson in a stable form from the dimethyl sulfoxide solvated form of regadenoson, which preparation is purifiable and scalable.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: December 27, 2022
    Assignee: Macfarlan Smith Limited
    Inventor: Padmini Kavuru
  • Patent number: 11530234
    Abstract: CD73 (also known as ecto-5?-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I and pharmaceutically acceptable esters or salts thereof.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: December 20, 2022
    Inventors: Jiasheng Lu, Jiamin Gu, Gang Chen, Feng Zhou, Qiguo Zhang, Xuli Wang, Xiang Ji, Lin Wang, Xianqi Kong
  • Patent number: 11524975
    Abstract: The present invention relates to an amphiphilic compound having a dendronic hydrophobic group, a method for preparing the same, and a method for extraction, solubilization, stabilization, or crystallization of a membrane protein by using the same. The use of the compound according to the present invention leads to an excellent membrane protein solubilization effect and a stable storage of a membrane protein in an aqueous solution for a long time, and thus can be utilized for functional analysis and structural analysis of the membrane protein. Especially, the amphiphilic compound having a dendronic hydrophobic group showed very remarkable characteristics in the visualization of protein composites through an electronic microscope.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: December 13, 2022
    Assignee: Industry-University Cooperation Foundation Hanyang University Erica Campus
    Inventors: Pil Seok Chae, Aiman Sadaf
  • Patent number: 11517581
    Abstract: Methods and compounds for preventing and/or treating Zika virus (ZIKA) infection. And methods to screen for compound to prevent or treat Zika virus infection.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: December 6, 2022
    Inventors: Shuofeng Yuan, Fuk Woo Jasper Chan, Kwok Yung Yuen, Helena Den Haan, Jorge Pena-García, José Pedro Cerón-Carrasco, Horacio Emilio Pérez-Sánchez
  • Patent number: 11518777
    Abstract: The present invention relates to novel inhibitors of the shikimate pathway (shikimic acid pathway), pharmaceutical compositions comprising these novel inhibitors, methods for the production of the inhibitors and their use as antibiotics and herbicides.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: December 6, 2022
    Assignee: Eberhard Karls Universität Tübingen
    Inventors: Stephanie Grond, Karl Forchhammer, Klaus Brilisauer
  • Patent number: 11505571
    Abstract: This disclosure features chemical entities (e.g., a compound that modulates (e.g., agonizes) Stimulator of Interferon Genes (STING), or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that are useful, e.g., for treating a condition, disease or disorder in which a decrease or increase in STING activity (e.g., a decrease, e.g., a condition, disease or disorder associated with repressed or impaired STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: November 22, 2022
    Assignee: Innate Tumor Immunity, Inc.
    Inventors: Gary Glick, Shomir Ghosh, Edward James Olhava, William R. Roush, Roger Jones
  • Patent number: 11505569
    Abstract: This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: November 22, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Nanna Albaek, Jacob Ravn, Christoph Rosenbohm
  • Patent number: 11485753
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: November 1, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
  • Patent number: 11485751
    Abstract: The invention relates to derivatives of apramycin-based aminoglycoside antibacterial drugs modified in positions C5 and/or C6 and O5 and/or O6. The modifications impart favourable properties regarding increased selectivity and retention of activity in the presence of resistance determinants of the AAC(3) class. The invention further relates to said compounds for use in the therapy of bacterial infection by systemic administration, especially in instances where the infection is caused by a pathogen comprising a resistance determinant of the AAC(3) class, in particular AAC(3)-IV.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: November 1, 2022
    Inventors: Erik C. Bottger, Sven N. Hobbie, Andrea Vasella, David Crich, Amr Sonousi, Takayuki Kato, Jonathan Quirke, Parasuraman Rajasekaran, Vikram Ashok Sarpe